刚才看到朋友发给我的Seres的消息:Seres Therapeutics Inc. shares were down 56% to $9.27 after the company said topline results from its Phase 2b study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis didn't meet its primary endpoint of improving clinical remission rates compared with placebo.Seres的药物SER-287在针对溃疡性结肠炎的II期实验结果不理想,导致股价暴跌,目前的价格为8.99美元,市值8.24亿美元。